IXICO (PHYOF) Return-on-Tangible-Asset: -35.40% (As of Mar. 2026)


PHYOF IXICO PLC PHYOF
42 GF Score
Price $0.07
GF Value $0.07
! 2 Warning Signs
View Full Analysis

What is IXICO Return-on-Tangible-Asset?

IXICO PHYOF -53.33% 42 Return-on-Tangible-Asset is -35.40% as of Mar. 2026. GuruFocus rates PHYOF with a GF Score™ of 42/100 and a GF Value™ of $0.07. The stock has 2 warning signs investors should review. Among 1,413 Biotechnology companies, IXICO ranks better than 56.83% on this metric.

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. IXICO's annualized Net Income for the quarter that ended in Mar. 2026 was $-3.00 Mil. IXICO's average total tangible assets for the quarter that ended in Mar. 2026 was $8.47 Mil. Therefore, IXICO's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -35.40%.

The historical rank and industry rank for IXICO's Return-on-Tangible-Asset or its related term are showing as below:

PHYOF' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -46.77   Med: -11.52   Max: 13.16
Current: -27.06

During the past 13 years, IXICO's highest Return-on-Tangible-Asset was 13.16%. The lowest was -46.77%. And the median was -11.52%.

PHYOF's Return-on-Tangible-Asset is ranked better than
56.83% of 1413 companies
in the Biotechnology industry
Industry Median: -35.77 vs PHYOF: -27.06

IXICO  (OTCPK:PHYOF) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


IXICO Return-on-Tangible-Asset Related Terms


IXICO Return-on-Tangible-Asset Historical Data

* Premium members only.

The historical data trend for IXICO's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IXICO Return-on-Tangible-Asset Chart

IXICO Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.54 8.57 -14.67 -35.68 -29.05

IXICO Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -47.36 -23.83 -30.76 -19.99 -35.40

PHYOF vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison

For the Biotechnology subindustry, IXICO's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IXICO Return-on-Tangible-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IXICO's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where IXICO's Return-on-Tangible-Asset falls into.


PHYOF
42GF Score
IXICO PLC PHYOF
Return-on-Tangible-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IXICO Return-on-Tangible-Asset Calculation

IXICO's annualized Return-on-Tangible-Asset for the fiscal year that ended in Sep. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Sep. 2025 )  (A: Sep. 2024 )(A: Sep. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Sep. 2025 )  (A: Sep. 2024 )(A: Sep. 2025 )
=-2.231/( (6.368+8.994)/ 2 )
=-2.231/7.681
=-29.05 %

IXICO's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=-2.998/( (8.994+7.946)/ 2 )
=-2.998/8.47
=-35.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Mar. 2026) net income data.

What does a Return-on-Tangible-Asset of -35.40% mean?
IXICO (PHYOF) has a Return-on-Tangible-Asset of -35.40% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on IXICO and its competitors. According to the industry distribution chart, IXICO ranks #610 out of 1413 companies in the Biotechnology industry, placing it in the top 43.2%.
Is IXICO's Return-on-Tangible-Asset too high?
IXICO's current Return-on-Tangible-Asset is -35.40%. Based on the distribution chart, IXICO ranks #610 out of 1413 companies in the Biotechnology industry, which is above the industry midpoint. Overall, IXICO has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does IXICO's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, IXICO ranks #610 out of 1413 companies for Return-on-Tangible-Asset. This puts IXICO in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on IXICO and its competitors. IXICO's current Return-on-Tangible-Asset is -35.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IXICO stock overvalued right now?
IXICO (PHYOF) has a current Return-on-Tangible-Asset of -35.40%. The stock's GF Value™ is $0.07, compared to a current price of $0.07 — trading right at its estimated fair value. The current Return-on-Tangible-Asset is -35.40%. IXICO's overall GF Score™ is 42/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For IXICO (PHYOF), the current Return-on-Tangible-Asset is -35.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IXICO (PHYOF) Overvalued in 2026?

Based on GuruFocus' analysis, IXICO stock appears to be undervalued. The current stock price of $0.07 is trading 0% below its estimated GF Value™ of $0.07.

Key valuation signals for PHYOF:

  • Return-on-Tangible-Asset: -35.40%
  • GF Value™: $0.07 vs. price of $0.07 (0% below fair value)
  • GF Score™: 42/100 with 2 warning signs

No single metric tells the full story. See the PHYOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


IXICO Business Description

Other Exchanges IXI:UK
Address 15 Long Lane, 4th Floor, Griffin Court, London, GBR, EC1A 9PN
IXICO PLC provides neuroscience imaging and biomarker analytics services, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. It operates as an imaging contract research organization, supporting clinical trials for neurological disorders by processing and analyzing imaging data. Its platform is used to measure biomarkers associated with diseases such as Alzheimer's, Huntington's, and Parkinson's.
42GF Score

Get the complete analysis for PHYOF

Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.07
Price
$0.07
GF Value